+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

Gastroenterology 143(3): 629-36.E1

(PDF emailed within 0-6 h: $19.90)

Accession: 056048552

Download citation: RISBibTeXText

PMID: 22659218

DOI: 10.1053/j.gastro.2012.05.039

Related references

Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. Journal of Clinical Virology 58(4): 713-717, 2014

HBsAg Loss is Enough to Discontinue Long-Term Nucleos (T)IDE Analogue Therapy in HBeAg-Negative Chronic Hepatitis B Patients in Real Practice?. Journal of Hepatology 64(2): S370-S371, 2016

Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment. Zhonghua Gan Zang Bing Za Zhi 16(6): 416-420, 2008

Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. Antiviral Therapy 18(7): 895-904, 2014

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135(2): 459-467, 2008

Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. Journal of Infectious Diseases, 2018

Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver International 31(10): 1525-1532, 2012

Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in noncirrhotic HBeAg-negative chronic hepatitis B patients: Results from the DARING-B prospective Greek study. Journal of Hepatology 68: S88-S89, 2018

DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antiviral Therapy, 2018

Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antiviral Therapy 12(1): 73-82, 2007

Undetectable serum HBV-DNA by quantitative PCR at the end of interferon treatment A predictor of sustained response and HBsAg clearance in patients with HBeAg-negative chronic hepatitis B. Hepatology 30(4 PART 2): 350A, 1999

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. New England Journal of Medicine 352(26): 2673-2681, 2005

Long-Term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. Yearbook of Pediatrics 2007: 156-157, 2007

Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. Hepatology Research 46(10): 992-1001, 2015

Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B. Gastroenterologia Y Hepatologia 34(2): 69-74, 2011